India-based Lupin has appointed former Teva senior VP Dr Maurice Chagnaud as president of its European business and head of inhalation strategy.
Dr Chagnaud will be based at the company’s operations in Schaffhausen, Switzerland, where he will be responsible for Lupin’s business strategy in Europe, including Russia and the CIS countries.
He will also be responsible for developing Lupin’s core strategy for inhalation across all developed markets.
Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva. He was with Teva for just under seven years, with other roles include chief commercial officer in Europe and CEO of the company’s operations in France.
In addition, Dr Chagnaud’s industry experience also includes time as general manager for Merck KGaA’a generics business in Italy.